11/19/2026 | Press release | Distributed by Public on 11/19/2026 16:31
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
29,264
|
$
|
24,147
|
||||
|
Prepaid expenses and other current assets
|
5,527
|
1,208
|
||||||
|
Total current assets
|
34,791
|
25,355
|
||||||
|
Restricted cash
|
2,366
|
2,029
|
||||||
|
Operating lease right-of-use assets
|
14,075
|
14,959
|
||||||
|
Property and equipment, net
|
10,261
|
12,595
|
||||||
|
Other non-current assets
|
1,160
|
1,431
|
||||||
|
Total assets
|
$
|
62,653
|
$
|
56,369
|
||||
|
Liabilities, Convertible Preferred Stock and Stockholders' Deficit
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
8,937
|
$
|
3,383
|
||||
|
Accrued expenses and other current liabilities
|
7,416
|
3,707
|
||||||
|
Operating lease liability, current portion
|
2,320
|
1,682
|
||||||
|
Deferred revenue, current portion
|
10,226
|
14,464
|
||||||
|
2026 Notes payable (includes $16,053 and $0 from related parties)
|
30,100
|
-
|
||||||
|
Total current liabilities
|
58,999
|
23,236
|
||||||
|
2025 Notes payable, related party
|
38,500
|
13,100
|
||||||
|
2023 Warrants and Letter Warrant liability (includes $345 and $6,170 from related parties)
|
354
|
6,286
|
||||||
|
2025 Warrant liability, related party
|
1,600
|
1,388
|
||||||
|
Pre-funded warrant liability, Series Seed convertible preferred stock
|
14,041
|
-
|
||||||
|
Pre-funded warrant liability, Series A convertible preferred stock
|
35,856
|
-
|
||||||
|
Pre-funded warrant liability, Series B convertible preferred stock
|
66,233
|
-
|
||||||
|
Contingent tranche liability, related party
|
-
|
500
|
||||||
|
Operating lease liability, net of current portion
|
19,947
|
21,736
|
||||||
|
Deferred revenue, net of current portion
|
26,217
|
60,143
|
||||||
|
Total liabilities
|
261,747
|
126,389
|
||||||
|
Commitments and contingencies (Note 16)
|
||||||||
|
Convertible preferred stock (Series Seed, A and B), $0.0001 par value;
124,133,326 shares authorized at both September 30, 2026
and December 31, 2025; 33,026,156 and 118,136,265 shares issued and
outstanding at September 30, 2026 and December 31, 2025,
respectively; aggregate liquidation preference of $58,557 and
$219,390 at September 30, 2026 and December 31, 2025, respectively
|
53,765
|
200,865
|
||||||
|
Stockholders' deficit:
|
||||||||
|
Common stock, $0.0001 par value; 162,000,000 shares authorized at both September 30, 2026 and December 31, 2025; 5,201,899 and 7,811,834 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
|
1
|
1
|
||||||
|
Additional paid-in capital
|
53,574
|
21,110
|
||||||
|
Accumulated deficit
|
(306,434
|
)
|
(291,996
|
)
|
||||
|
Total stockholders' deficit
|
(252,859
|
)
|
(270,885
|
)
|
||||
|
Total liabilities, convertible preferred stock and stockholders' deficit
|
$
|
62,653
|
$
|
56,369
|
||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Collaboration revenue
|
$
|
46,164
|
$
|
2,509
|
||||
|
Operating expenses:
|
||||||||
|
Research and development
|
40,880
|
43,474
|
||||||
|
General and administrative
|
15,894
|
11,899
|
||||||
|
Total operating expenses
|
56,774
|
55,373
|
||||||
|
Loss from operations
|
(10,610
|
)
|
(52,864
|
)
|
||||
|
Other (expense) income:
|
||||||||
|
Change in fair value of convertible notes payable, warrant liabilities and contingent tranche liability, related party
|
(4,280
|
)
|
(3,580
|
)
|
||||
|
Interest income
|
473
|
1,127
|
||||||
|
Other expense, net
|
(21
|
)
|
(24
|
)
|
||||
|
Total other expense, net
|
(3,828
|
)
|
(2,477
|
)
|
||||
|
Loss before income taxes
|
(14,438
|
)
|
(55,341
|
)
|
||||
|
Income tax expense (benefit)
|
-
|
(174
|
)
|
|||||
|
Net loss and comprehensive loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Deemed contribution related to preferred stock exchange
|
30,970
|
-
|
||||||
|
Less: Earnings allocated to participating preferred securities
|
(16,319
|
)
|
-
|
|||||
|
Net income (loss) attributable to common stockholders
|
$
|
213
|
$
|
(55,167
|
)
|
|||
|
Weighted-average common shares outstanding - basic
|
7,918,093
|
7,689,038
|
||||||
|
Weighted-average common shares outstanding - diluted
|
51,127,610
|
7,689,038
|
||||||
|
Net income (loss) per share of common stock - basic
|
$
|
0.03
|
$
|
(7.17
|
)
|
|||
|
Net income (loss) per share of common stock - diluted
|
$
|
(0.42
|
)
|
$
|
(7.17
|
)
|
||
|
Series Seed, A and B
Convertible Preferred Stock
|
Common Stock
|
Additional
Paid-In
|
Accumulated
|
Total
Stockholders'
|
||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Deficit
|
||||||||||||||||||||||
|
Balance at December 31, 2024
|
87,203,974
|
$
|
132,793
|
7,626,774
|
$
|
1
|
$
|
18,818
|
$
|
(218,291
|
)
|
$
|
(199,472
|
)
|
||||||||||||||
|
Net loss
|
-
|
-
|
-
|
-
|
-
|
(55,167
|
)
|
(55,167
|
)
|
|||||||||||||||||||
|
Stock-based compensation expense
|
-
|
-
|
-
|
-
|
1,714
|
-
|
1,714
|
|||||||||||||||||||||
|
Exercise of stock options
|
-
|
-
|
88,220
|
-
|
49
|
-
|
49
|
|||||||||||||||||||||
|
Balance at September 30, 2025
|
87,203,974
|
$
|
132,793
|
7,714,994
|
$
|
1
|
$
|
20,581
|
$
|
(273,458
|
)
|
$
|
(252,876
|
)
|
||||||||||||||
|
Balance at December 31, 2025
|
118,136,265
|
$
|
200,865
|
7,811,834
|
$
|
1
|
$
|
21,110
|
$
|
(291,996
|
)
|
$
|
(270,885
|
)
|
||||||||||||||
|
Net loss
|
-
|
-
|
-
|
-
|
-
|
(14,438
|
)
|
(14,438
|
)
|
|||||||||||||||||||
|
Exchange of common stock for pre-funded warrants
|
-
|
-
|
(3,000,000
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||
|
Exchange of convertible preferred stock (Series Seed, A and B) for pre-funded warrants
|
(85,110,109
|
)
|
(147,100
|
)
|
-
|
-
|
30,970
|
-
|
30,970
|
|||||||||||||||||||
|
Stock-based compensation expense
|
-
|
-
|
-
|
-
|
1,237
|
-
|
1,237
|
|||||||||||||||||||||
|
Exercise of stock options
|
-
|
-
|
390,065
|
-
|
257
|
-
|
257
|
|||||||||||||||||||||
|
Balance at September 30, 2026
|
33,026,156
|
$
|
53,765
|
5,201,899
|
$
|
1
|
$
|
53,574
|
$
|
(306,434
|
)
|
$
|
(252,859
|
)
|
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization expense
|
2,049
|
2,390
|
||||||
|
Stock-based compensation expense
|
1,237
|
1,714
|
||||||
|
Change in fair value of convertible notes payable, warrant liabilities and
contingent tranche liability, related party
|
4,280
|
3,580
|
||||||
|
Amortization of deferred issuance costs
|
-
|
203
|
||||||
|
Loss on disposal and sale of property and equipment
|
244
|
5
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
-
|
353
|
||||||
|
Prepaid expenses and other assets
|
(265
|
)
|
907
|
|||||
|
Accounts payable
|
3,201
|
(3,036
|
)
|
|||||
|
Accrued expenses and other current liabilities
|
3,199
|
(422
|
)
|
|||||
|
Operating lease liabilities
|
(266
|
)
|
(893
|
)
|
||||
|
Deferred revenue
|
(38,164
|
)
|
(2,509
|
)
|
||||
|
Net cash used in operating activities
|
(38,923
|
)
|
(52,875
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
(6
|
)
|
(42
|
)
|
||||
|
Proceeds from sales of property and equipment
|
54
|
-
|
||||||
|
Net cash provided by (used in) investing activities
|
48
|
(42
|
)
|
|||||
|
Cash flows from financing activities:
|
||||||||
|
Payment of deferred issuance costs
|
(286
|
)
|
-
|
|||||
|
Issuance costs for convertible promissory note
|
(642
|
)
|
-
|
|||||
|
Proceeds from issuance of convertible notes payable
|
45,000
|
-
|
||||||
|
Proceeds from exercise of stock options
|
257
|
49
|
||||||
|
Net cash provided by financing activities
|
44,329
|
49
|
||||||
|
Net increase (decrease) in cash, cash equivalents and restricted cash
|
5,454
|
(52,868
|
)
|
|||||
|
Cash, cash equivalents and restricted cash, beginning of period
|
26,176
|
75,522
|
||||||
|
Cash, cash equivalents and restricted cash, end of period
|
$
|
31,630
|
$
|
22,654
|
||||
|
Supplemental disclosures of non-cash information:
|
||||||||
|
Offering costs accrued but not yet paid
|
$
|
3,506
|
$
|
-
|
||||
|
Exchange of common stock and convertible preferred stock for pre-funded warrants (see Note 1)
|
116,130
|
-
|
||||||
|
September 30, 2026
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
24,395
|
$
|
-
|
$
|
-
|
$
|
24,395
|
||||||||
|
$
|
24,395
|
$
|
-
|
$
|
-
|
$
|
24,395
|
|||||||||
|
Liabilities:
|
||||||||||||||||
|
2026 Notes payable
|
$
|
-
|
$
|
-
|
$
|
30,100
|
$
|
30,100
|
||||||||
|
2025 Notes payable
|
-
|
-
|
38,500
|
38,500
|
||||||||||||
|
2023 Warrant liability*
|
-
|
-
|
354
|
354
|
||||||||||||
|
2025 Warrant liability
|
-
|
-
|
1,600
|
1,600
|
||||||||||||
|
Pre-funded warrant liability, Series Seed convertible preferred stock
|
-
|
-
|
14,041
|
14,041
|
||||||||||||
|
Pre-funded warrant liability, Series A convertible preferred stock
|
-
|
-
|
35,856
|
35,856
|
||||||||||||
|
Pre-funded warrant liability, Series B convertible preferred stock
|
-
|
-
|
66,233
|
66,233
|
||||||||||||
|
$
|
-
|
$
|
-
|
$
|
186,684
|
$
|
186,684
|
|||||||||
|
*
|
The 2023 Warrant liability includes warrants issued to obtain a line of credit amounting to less than $0.1 million as of September 30, 2026.
|
|
December 31, 2025
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
15,433
|
$
|
-
|
$
|
-
|
$
|
15,433
|
||||||||
|
$
|
15,433
|
$
|
-
|
$
|
-
|
$
|
15,433
|
|||||||||
|
Liabilities:
|
||||||||||||||||
|
2025 Notes payable
|
$
|
-
|
$
|
-
|
$
|
13,100
|
$
|
13,100
|
||||||||
|
2023 Warrant liability*
|
-
|
-
|
6,286
|
6,286
|
||||||||||||
|
2025 Warrant liability
|
-
|
-
|
1,388
|
1,388
|
||||||||||||
|
Contingent tranche liability
|
-
|
-
|
500
|
500
|
||||||||||||
|
$
|
-
|
$
|
-
|
$
|
21,274
|
$
|
21,274
|
|||||||||
|
*
|
The 2023 Warrant liability includes warrants issued to obtain a line of credit amounting to $0.1 million as of December 31, 2025.
|
|
2026
Notes
payable
|
2025
Notes
payable
|
2023
Warrant
liability*
|
2025
Warrant
liability
|
Contingent
tranche liability
|
Pre-funded
warrant
liability,
Series Seed
convertible
preferred
stock
|
Pre-funded
warrant
liability,
Series A
convertible
preferred
stock
|
Pre-funded
warrant
liability,
Series B
convertible
preferred
stock
|
|||||||||||||||||||||||||
|
Balance at December 31, 2025
|
$
|
-
|
$
|
13,100
|
$
|
6,286
|
$
|
1,388
|
$
|
500
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||||||||||||
|
Issuances
|
30,000
|
13,500
|
-
|
1,500
|
-
|
14,041
|
35,856
|
66,233
|
||||||||||||||||||||||||
|
Adjustments to estimated fair value
|
100
|
11,900
|
(5,932
|
)
|
(1,288
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||
|
Settlements
|
-
|
-
|
-
|
-
|
(500
|
)
|
-
|
-
|
-
|
|||||||||||||||||||||||
|
Balance at September 30, 2026
|
$
|
30,100
|
$
|
38,500
|
$
|
354
|
$
|
1,600
|
$
|
-
|
$
|
14,041
|
$
|
35,856
|
$
|
66,233
|
||||||||||||||||
|
2025 Notes payable
|
2023 Warrant
liability*
|
|||||||
|
Balance at December 31, 2024
|
$
|
59,600
|
$
|
4,136
|
||||
|
Adjustments to estimated fair value
|
4,300
|
(720
|
)
|
|||||
|
Balance at September 30, 2025
|
$
|
63,900
|
$
|
3,416
|
||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Risk-free interest rate
|
3.90% - 4.40%
|
|
3.62% - 3.90%
|
|
||||
|
Expected dividend rate
|
0.00%
|
|
0.00%
|
|
||||
|
Expected stock price volatility
|
77.00% - 91.00%
|
|
48.00% - 94.00%
|
|
||||
|
Expected term (years)
|
0.16 - 1.83
|
0.25 - 2.00
|
||||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Risk-free interest rate
|
3.90% - 4.40%
|
|
3.60% - 3.70%
|
|
||||
|
Expected dividend rate
|
0.00%
|
|
0.00%
|
|
||||
|
Expected stock price volatility
|
61.00% - 105.9%
|
|
85.90% - 95.00%
|
|
||||
|
Expected term (years)
|
0.16 - 1.83
|
1.00 - 2.00
|
||||||
|
September 30,
2026
|
December 31,
2025
|
September 30,
2025
|
December 31,
2024
|
|||||||||||||
|
Cash and cash equivalents
|
$
|
29,264
|
$
|
24,147
|
$
|
20,632
|
$
|
73,424
|
||||||||
|
Restricted cash
|
2,366
|
2,029
|
2,022
|
2,098
|
||||||||||||
|
$
|
31,630
|
$
|
26,176
|
$
|
22,654
|
$
|
75,522
|
|||||||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Leasehold improvements
|
$
|
14,100
|
$
|
14,100
|
||||
|
Laboratory equipment
|
7,233
|
7,523
|
||||||
|
Furniture and fixtures
|
798
|
798
|
||||||
|
Computer equipment and software
|
250
|
250
|
||||||
|
22,381
|
22,671
|
|||||||
|
Less: Accumulated depreciation and amortization
|
(12,120
|
)
|
(10,076
|
)
|
||||
|
$
|
10,261
|
$
|
12,595
|
|||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Prepaid expenses and other current assets
|
$
|
1,735
|
$
|
1,208
|
||||
|
Deferred issuance costs
|
3,792
|
-
|
||||||
|
$
|
5,527
|
$
|
1,208
|
|||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Accrued research and development costs
|
$
|
4,201
|
$
|
1,862
|
||||
|
Accrued employee compensation and benefits
|
2,006
|
1,414
|
||||||
|
Accrued professional services and other
|
1,209
|
431
|
||||||
|
$
|
7,416
|
$
|
3,707
|
|||||
|
September 30, 2026
|
||||||||||||||||||||
|
Shares
Authorized
|
Shares
Issued and
Outstanding
|
Carrying
Value
|
Liquidation
Preference
|
Common Stock
Issuable Upon
Conversion
|
||||||||||||||||
|
Series Seed Preferred Stock
|
17,964,705
|
7,564,454
|
$
|
7,032
|
$
|
7,158
|
7,564,454
|
|||||||||||||
|
Series A Preferred Stock
|
35,714,365
|
9,296,900
|
15,083
|
17,647
|
9,296,900
|
|||||||||||||||
|
Series B Preferred Stock
|
70,454,256
|
16,164,802
|
31,650
|
33,752
|
16,164,802
|
|||||||||||||||
|
124,133,326
|
33,026,156
|
$
|
53,765
|
$
|
58,557
|
33,026,156
|
||||||||||||||
|
December 31, 2025
|
||||||||||||||||||||
|
Shares
Authorized
|
Shares
Issued and
Outstanding
|
Carrying
Value
|
Liquidation
Preference
|
Common Stock
Issuable Upon
Conversion
|
||||||||||||||||
|
Series Seed Preferred Stock
|
17,964,705
|
17,964,705
|
$
|
16,700
|
$
|
17,000
|
17,964,705
|
|||||||||||||
|
Series A Preferred Stock
|
35,714,365
|
35,661,683
|
57,856
|
67,693
|
35,661,683
|
|||||||||||||||
|
Series B Preferred Stock
|
70,454,256
|
64,509,877
|
126,309
|
134,697
|
64,509,877
|
|||||||||||||||
|
124,133,326
|
118,136,265
|
$
|
200,865
|
$
|
219,390
|
118,136,265
|
||||||||||||||
|
Shares Exchanged
|
||||
|
Series Seed Preferred Stock
|
10,400,251
|
|||
|
Series A Preferred Stock
|
26,364,783
|
|||
|
Series B Preferred Stock
|
48,345,075
|
|||
|
Total
|
85,110,109
|
|||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Shares reserved for the conversion of authorized Series Seed
Preferred Stock
|
17,964,705
|
17,964,705
|
||||||
|
Shares reserved for the conversion of authorized Series A Preferred Stock
|
35,714,365
|
35,714,365
|
||||||
|
Shares reserved for the conversion of authorized Series B Preferred Stock*
|
70,454,256
|
70,454,256
|
||||||
|
Common shares reserved for exercise of pre-funded warrants
|
3,000,000
|
-
|
||||||
|
Common stock options available for grant under the 2019 Plan
|
1,720,290
|
4,553,047
|
||||||
|
Common stock options outstanding under the 2019 Plan
|
19,371,301
|
16,928,609
|
||||||
|
148,224,917
|
145,614,982
|
|||||||
|
*
|
Includes shares of 2023 Warrants and Letter Warrants at both September 30, 2026 and December 31, 2025.
|
|
Number
of Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Life
|
Aggregate
Intrinsic
Value
|
|||||||||||||
|
(in years)
|
(in thousands)
|
|||||||||||||||
|
Outstanding at December 31, 2025
|
16,928,609
|
$
|
0.75
|
5.94
|
$
|
7,179
|
||||||||||
|
Granted
|
5,378,960
|
$
|
1.15
|
|||||||||||||
|
Exercised
|
(390,065
|
)
|
$
|
0.66
|
||||||||||||
|
Forfeited or canceled
|
(2,546,203
|
)
|
$
|
0.80
|
||||||||||||
|
Outstanding at September 30, 2026
|
19,371,301
|
$
|
0.85
|
6.98
|
$
|
5,420
|
||||||||||
|
Vested and expected to vest at September 30, 2026
|
18,879,278
|
$
|
0.84
|
6.94
|
$
|
5,420
|
||||||||||
|
Exercisable at September 30, 2026
|
12,370,156
|
$
|
0.69
|
5.71
|
$
|
5,301
|
||||||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
General and administrative expense
|
$
|
505
|
$
|
1,054
|
||||
|
Research and development expense
|
732
|
660
|
||||||
|
$
|
1,237
|
$
|
1,714
|
|||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Numerator:
|
||||||||
|
Net loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Deemed dividend on exchange of Series Seed convertible preferred stock
|
(4,372
|
)
|
-
|
|||||
|
Deemed contributions on exchange of Series A and Series B convertible preferred stock
|
35,342
|
-
|
||||||
|
Net income (loss) attributable to common shareholders and participating securities
|
$
|
16,532
|
$
|
(55,167
|
)
|
|||
|
Less: 8% noncumulative dividend preference allocated to participating securities
|
(13,127
|
)
|
-
|
|||||
|
Less: remaining undistributed earnings allocated to participating securities
|
(3,192
|
)
|
-
|
|||||
|
Net income (loss) allocated to common stockholders, basic
|
$
|
213
|
$
|
(55,167
|
)
|
|||
|
Add: undistributed earnings allocated to Series B convertible preferred stock exchanged under the Exchange Agreements
|
6,566
|
-
|
||||||
|
Less: reversal of deemed contribution on Series B convertible preferred stock exchanged under the Exchange Agreements
|
(28,426
|
)
|
-
|
|||||
|
Net income (loss) attributable to common stockholders, diluted
|
$
|
(21,647
|
)
|
$
|
(55,167
|
)
|
||
|
Denominator:
|
||||||||
|
Weighted-average common shares outstanding, basic
|
7,918,093
|
7,689,038
|
||||||
|
Add: Series B convertible preferred stock exchanged under the Exchange Agreements, as converted
|
43,209,517
|
-
|
||||||
|
Weighted-average common shares outstanding, diluted
|
51,127,610
|
7,689,038
|
||||||
|
Net income (loss) per share attributable to common stockholders, basic
|
$
|
0.03
|
$
|
(7.17
|
)
|
|||
|
Net income (loss) per share attributable to common stockholders, diluted
|
$
|
(0.42
|
)
|
$
|
(7.17
|
)
|
||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Convertible preferred stock (as converted to common stock)
|
33,026,156
|
87,203,974
|
||||||
|
Stock options to purchase common stock
|
19,371,301
|
17,688,691
|
||||||
|
Pre-funded warrants to purchase convertible preferred stock
|
85,110,109
|
-
|
||||||
|
Warrants issued in relation to a line of credit
|
143,549
|
143,549
|
||||||
|
Warrants issued in relation to 2023 convertible promissory notes payable
|
5,753,715
|
-
|
||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Collaboration revenue
|
$
|
46,164
|
$
|
2,509
|
||||
|
Research and development expenses:
|
||||||||
|
Personnel costs
|
7,582
|
11,342
|
||||||
|
MYB program
|
23,206
|
16,241
|
||||||
|
Other preclinical programs
|
4,311
|
8,821
|
||||||
|
Facilities, laboratory supplies and other
|
5,781
|
7,070
|
||||||
|
General and administrative expenses:
|
||||||||
|
Personnel costs
|
4,019
|
4,605
|
||||||
|
Facilities, laboratory supplies and other
|
11,875
|
7,294
|
||||||
|
Other segment items*
|
3,828
|
2,303
|
||||||
|
Net loss and comprehensive loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||